Accessibility Menu
Drugs Made In America Acquisition Corp. logo

Drugs Made In America Acquisition Corp.(NASDAQ) DMAA

Current Price$10.67
Market Cap$259.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+7%
5 YearN/A
1 Year+4%
1 Month+1%
Drugs Made In America Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 10.702026-07-22
Drugs Made In America Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.19%USD 10.682026-07-15
1 month+0.66%USD 10.632026-06-22
3 month+1.52%USD 10.542026-04-23
Year to date+3.14%USD 10.372025-12-31
1 year+4.29%USD 10.262025-07-22
Since inception+7.43%USD 9.962025-02-25

Drugs Made In America Acquisition Corp. Financials at a Glance

Market Cap

$259.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.66M

EPS (TTM)

$0.20

P/E Ratio

53.99

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Price

$10.67

Volume

100

Open

$10.67

Previous Close

$10.70

Daily Range

$10.67 - $10.67

52-Week Range

$10.22 - $10.70

Estimated Earnings Date

May 20, 2025

DMAA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Drugs Made In America Acquisition Corp.

Drugs Made In America helps private businesses enter the stock market. It acts as a shell to buy and merge with other firms. The company currently searches for partners in medicine and technology.

What Does This Company Do?

  • Blank Check Services: Acting as a vehicle for private companies to go public through a merger.
  • Target Identification: Finding and evaluating businesses in the artificial intelligence and pharmaceutical sectors.
  • Capital Hosting: Managing funds held in a trust account for a future acquisition.

Moves to Make a Match

  • Entered a letter of intent on April 7, 2026, to merge with Power Analytics Global Corp.
  • Issued an interim convertible note to BV Advisory Partners, LLC for $100,000 in March 2026.
  • Appointed Roger Bendelac as Chief Executive Officer in February 2026 to lead the management team.

What Sets the Team Apart

The firm focuses on US-based industries that require rapid innovation and scaling. It maintains a trust account of over $241 million to support its eventual business combination.

Key Financial Figures

  • Net income hit $5.9 million in 2025, largely from interest earned on cash.
  • Operating income was -$2.1 million in Q4 2025, which worsened from the prior year.
  • The trust account held $241.3 million as of March 6, 2026.
  • Transaction costs for the initial public offering totaled $8.9 million in early 2025.

Bottom Line

The company has shifted from its initial public offering to active deal-making in the technology sector. Its success depends on completing a merger before its regulatory deadlines.

AI Generated • May 8, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Roger Emile Bendelac, MBA

Website

www.dmaacorp.com

Headquarters

New York, NY 33301, US

DMAA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.88%

Return on Capital

-1.21%

Return on Assets

2.75%

Earnings Yield

1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$259.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.28M

Volume

100

Avg. Volume

36.29K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.63M

EBITDA

-$2.63M

Operating Cash Flow

-$379.19K

Capital Expenditure

-$4.00

Free Cash Flow

-$379.19K

Cash & ST Invst.

$14.89K

Total Debt

$100.00K

Drugs Made In America Acquisition Corp. Performance Analysis

Drugs Made In America Acquisition Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Drugs Made In America Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Drugs Made In America Acquisition Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.01N/A
20252025-12-31USD 0.18N/A
Drugs Made In America Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-99.9%
Q32025-09-302.5%
Q42025-12-31-91.0%
Q12026-03-31852.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$259.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$129.88M

N/A

Employees

2

N/A

Net Income

$1.97M

+57.1%

EBITDA

-$143.30K

+56.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.89K

+1512.9%

Total Debt

$100.00K

+64.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$100.00K

+64.2%

Return on Assets

2.75%

N/A

Return on Invested Capital

-1.09%

N/A

Free Cash Flow

-$91.25K

+63.7%

Operating Cash Flow

-$91.25K

+63.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares
$10.49-0.38%
LOKVLive Oak Acquisition Corp. V Class A Ordinary Shares
$11.52+0.00%
SIMASIM Acquisition Corp. I
$10.85-0.82%
OYSEOyster Enterprises II Acquisition Corp
$10.31+0.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.96-0.27%
AALAmerican Airlines Group
$13.43-0.09%
TQQQProShares Trust - ProShares UltraPro Qqq
$66.54-0.05%
HBANHuntington Bancshares
$17.34-0.05%

Questions About DMAA

What is the current price of Drugs Made In America Acquisition Corp.?

Drugs Made In America Acquisition Corp. is trading at $10.67 per share.

What is the 52-week range for Drugs Made In America Acquisition Corp.?

Over the past 52 weeks, Drugs Made In America Acquisition Corp. has traded between $10.22 and $10.70.

How much debt does Drugs Made In America Acquisition Corp. have?

As of the most recent reporting period, Drugs Made In America Acquisition Corp. reported total debt of $100.00K.

How much cash does Drugs Made In America Acquisition Corp. have on hand?

Drugs Made In America Acquisition Corp. reported $14.89K in cash and cash equivalents in its most recent financial results.

What is Drugs Made In America Acquisition Corp.’s dividend yield?

Drugs Made In America Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services